Business
Adicet is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Adicet kept losses roughly flat and drew large institutional buying, but cash burn rose and equity fell.
The read at a glance✓ Audited against SEC data
- Business mix — Allogeneic gamma delta T cell therapiesNote
- Revenue — No product revenue in local bundleNote
- Profitability — Net loss roughly flat at $116.8MNote
- Cash burn — Free cash flow was -$97.0MWatch
- Balance sheet — Equity -14.7% to $159.2MWatch
- Insiders — 4 buys / 2 sells; $5.1M boughtOK
- Accounting — No critical audit matters reportedNote
Leadership changes
From Adicet Bio, Inc.'s own filings, the day they're filed.
- Michael Grissinger · director · departureeff. 2025-04-17
- Carl L. Gordon · member of the board of directors · departureeff. 2025-04-14
- Lloyd Klickstein · director · appointmenteff. 2024-08-19
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-18
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Adicet Bio, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.